Skip to main navigation Skip to search Skip to main content

Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer

  • for Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups*
  • University of Oklahoma
  • Groupe Hospitalier Diaconesses–Croix
  • University of California at Los Angeles
  • Hospital de Sabadell
  • Royal Marsden NHS Foundation Trust
  • Catholic University of Sacred Heart
  • Yonsei University
  • Samsung Medical Center, Sungkyunkwan university
  • The University of Chicago
  • IRCCS Istituto Europeo di Oncologia - Milano
  • University of Milan - Bicocca
  • University of Medical Sciences Poznan
  • Academic Medical Centre
  • University of Massachusetts Boston
  • Meir Hospital Sapir Medical Center
  • Ohio State University
  • Charles University
  • University of Pennsylvania
  • CNRS
  • Arizona Oncology Associates
  • Hospital Universitario Virgen del Rocio
  • University of Pittsburgh
  • University College London
  • University of Virginia
  • IRCCS Istituto nazionale tumori Fondazione Giovanni Pascale - Napoli
  • Hospital Universitario de Jaén
  • ImmunoGen Inc
  • Institut Curie
  • KU Leuven

Research output: Contribution to journalArticlepeer-review

377 Scopus citations

Fingerprint

Dive into the research topics of 'Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer'. Together they form a unique fingerprint.
Sort by

Keyphrases

Medicine and Dentistry